Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ShangPharma Bumps Stock Price 28% Higher with Share Buyback

publication date: Aug 12, 2011
ShangPharma, a CRO that listed on the NYSE in late 2010, announced a share buyback program that may repurchase as much as $10 million of the company's stock over the next two years. The initiative was apparently made to support the company’s stock price, which dropped from $15 in the IPO to yesterday’s close of $7.70, a 49% haircut. Although buybacks often have little effect, ShangPharma’s ploy worked like magic: the company’s shares rose 28% by mid-session today, climbing $2.17 to $9.87. More details....

Stock Symbol: (NYSE: SHP)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital